Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO-3306
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- In Vitro (experimental Use), No Clinical Route Of Administration Established
01
Overview
**RO-3306** is a synthetic, selective, reversible, and ATP-competitive small molecule inhibitor of **cyclin-dependent kinase 1 (CDK1)**, with a \(K_i\) of 35 nM against CDK1/cyclin B1 and 110 nM against CDK1/cyclin A[1][2][4]. It exhibits 10-fold selectivity over CDK2 and at least 50-fold over CDK4[1]. RO-3306 induces **G2/M-phase cell cycle arrest and apoptosis**, and is widely used as a research tool for cell-cycle synchronization, particularly in cancer biology. It enhances downstream **p53 signaling** and acts synergistically with other agents to promote apoptosis, notably in acute myeloid leukemia and certain cancer cells[3][4].
- Other names
- (5Z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethylamino)-1,3-thiazol-4-oneCID 11631681CID11631681CID-11631681CAS 872573-93-8CAS872573-93-8CAS-872573-93-8
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK2 (Cyclin-dependent kinase 2)SGK1ERKPRKCD (Protein kinase C delta)CDK1 (Cyclin-dependent kinase 1)
Beyond the preview
Go deeper on RO-3306.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO-3306.